Karolinska Institute’s oncology spinout Aprea Therapeutics has received a $5.7m series C extension adding to an initial $56.8m close in November 2018 that featured Karolinska Development.

Aprea Therapeutics, a Sweden-based oncological drug developer spun out of Karolinska Institute, has increased its series C round to €55m ($62.8m) after securing a $5.7m contribution from unspecified funds managed by Janus Henderson Investors. The extension follows an initial $56.8m close announced in November 2018 that was led by Redmile Group with participation from the…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.